Literature DB >> 33658942

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance.

Yuqi Yang1, Zhuo-Xun Wu1, Jing-Quan Wang1, Qiu-Xu Teng1, Zi-Ning Lei1, Sabrina Lusvarghi2, Suresh V Ambudkar2, Zhe-Sheng Chen1, Dong-Hua Yang1.   

Abstract

OTS964 is a potent T-LAK cell-originated protein kinase (TOPK) inhibitor. Herein, we investigated the interaction of OTS964 and multidrug resistance (MDR)-associated ATP-binding cassette sub-family G member 2 (ABCG2). The cell viability assay indicated that the effect of OTS964 is limited in cancer drug-resistant and transfected cells overexpressing ABCG2. We found that the known ABCG2 transporter inhibitor has the ability to sensitize ABCG2-overexpressing cells to OTS964. In mechanism-based studies, OTS964 shows inhibitory effect on the efflux function mediated by ABCG2, and in turn, affects the pharmacokinetic profile of other ABCG2 substrate-drugs. Furthermore, OTS964 upregulates ABCG2 protein expression, resulting in enhanced resistance to ABCG2 substrate-drugs. The ATPase assay demonstrated that OTS964 stimulates ATPase activity of ABCG2 in a concentration-dependent manner. The computational molecular docking analysis combined with results from ATPase assay suggested that OTS964 interacts with drug-binding pocket of ABCG2 and has substrate-like behaviors. Thus, OTS964 is an MDR-susceptible agent due to its interactions with ABCG2, and overexpression of ABCG2 transporter may attenuate its therapeutic effect in cancer cells.
Copyright © 2021 Yang, Wu, Wang, Teng, Lei, Lusvarghi, Ambudkar, Chen and Yang.

Entities:  

Keywords:  ABC transporter; ABCG2; OTS964; TOPK inhibitor; cancer

Year:  2021        PMID: 33658942      PMCID: PMC7917255          DOI: 10.3389/fphar.2021.620874

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  6 in total

1.  MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study.

Authors:  Zhuo-Xun Wu; Qiu-Xu Teng; Yuqi Yang; Nikita Acharekar; Jing-Quan Wang; Min He; Sabesan Yoganathan; Jun Lin; Jian Wang; Zhe-Sheng Chen
Journal:  Acta Pharm Sin B       Date:  2021-12-30       Impact factor: 14.903

2.  PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study.

Authors:  Yuqi Yang; Qiu-Xu Teng; Zhuo-Xun Wu; Jing-Quan Wang; Zi-Ning Lei; Sabrina Lusvarghi; Suresh V Ambudkar; Ning Ji; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2022-02-08       Impact factor: 27.401

3.  The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.

Authors:  Han Fu; Zhuo-Xun Wu; Zi-Ning Lei; Qiu-Xu Teng; Yuqi Yang; Charles R Ashby; Yixiong Lei; Yuyin Lian; Zhe-Sheng Chen
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

4.  Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.

Authors:  Xing-Duo Dong; Meng Zhang; Chao-Yun Cai; Qiu-Xu Teng; Jing-Quan Wang; Yi-Ge Fu; Qingbin Cui; Ketankumar Patel; Dong-Tao Wang; Zhe-Sheng Chen
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

Review 5.  Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.

Authors:  Teodora Constantinescu; Alin Grig Mihis
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

6.  Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor.

Authors:  Zhuo-Xun Wu; Yuqi Yang; Jing-Quan Wang; Silpa Narayanan; Zi-Ning Lei; Qiu-Xu Teng; Leli Zeng; Zhe-Sheng Chen
Journal:  Front Cell Dev Biol       Date:  2021-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.